Page 221 - 2021 IDMT Digital
P. 221

LYMPHOMA
          Introduction:
            •  /\PSKRPD FDQ EH FDWHJRUL]HG DV +RGJNLQ RU QRQ +RGJNLQ O\PSKRPD DQG UHSUHVHQWV
               D FDQFHURXV SURFHVV JHQHUDOO\ SUHVHQWLQJ ZLWK SDLQOHVV  VZROOHQ O\PSK QRGHV LQ
               WKH QHFN
          Subjective:
            •  6LJQV DQG 6\PSWRPV
                 o  Non-+RGJNLQ
                       ƒ  Painless lymphadenopathy is predominant presenting symptom
                       ƒ  $JH QHDU
                 o  +RGJNLQ
                       ƒ  % s\PSWRPV  QLJKW VZHDWV  ZHLJKW ORVV  IHYHU  SUXULWXV
                       ƒ  ,QFUHDVHG O\PSK QRGH SDLQ ZLWK (t2+ LQJHVWLRQ (more
                         common with Hodgkin lymphoma)
                       ƒ  %L PRGDO DJH GLVWULEXWLRQ
                           •  $JH
                           •  $JH
          Objective:
            •  3K\VLFDO ([DP
                 o  96  IHYHU PD\ EH SUHVHQW
                 o  /\PSKDGHQRSDWK\
                 o  8QLQWHQWLRQDO ZHLJKW ORVV  !    ERG\ ZHLJKW LQ SUHYLRXV   PRQWKV
                 o  6SOHQRPHJDO\ KHSDWRPHJDO\
            •  7RROV
                 o  &%&  DQHPLD  SDQF\WRSHQLD
                 o  &;5  PHGLDVWLQDO HQODUJHPHQW
          Assessment:
            •  'LIIHUHQWLDO
                 o  +RGJNLQ  more likely to have % V\PSWRPV
                 o  1RQ +RGJNLQ  less likely to have % V\PSWRPV
                 o  /HXNHPLD  SUHVHQFH RI IHYHU  DQHPLD  FRQVWLWXWLRQDO V\PSWRPV
          Plan:
            •  ,I VXVSLFLRQ H[LVWV IRU O\PSKRPD  LPPHGLDWH HYDFXDWLRQ LV ZDUUDQWHG
          Patient Education:
            •  5HFRPPHQG FRXQVHOLQJ RQO\ EH GRQH E\ RQFRORJ\
            •  )ROORZ XS $FWLRQV
                 o  :LOO EH SHUIRUPHG E\ KRVSLWDO
          Preceptor Directive:
            •  Blue Directive: Contact Preceptor Immediately













                                         [ 220 ]
   216   217   218   219   220   221   222   223   224   225   226